1. BTAI hosts a roundtable on self-administered treatments for mental health. 2. Event discusses managing agitation in bipolar disorder and schizophrenia. 3. Experts highlight innovative approaches to patient care at home. 4. Significant patient need indicated by 57 to 77 million agitation episodes annually. 5. BTAI leverages AI to develop transformative treatment solutions.
FAQ
Why Bullish?
The focus on self-administered treatments could enhance BTAI's market position. Historically, innovation in treatment paradigms has positively influenced biotech valuations.
How important is it?
The discussion directly relates to BTAI's core therapeutic focus and potential future revenue streams. Increased attention to at-home treatments aligns with current healthcare trends, suggesting strong market relevance.
Why Short Term?
The upcoming event could lead to immediate investor interest and potential stock rallies. Similar past events have created short-term price movements.
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable on Neuropsychiatric Treatments
December 03, 2025 | Source: BioXcel Therapeutics
Virtual Event Details
On December 8, 2025, at 10 a.m. EST, award-winning healthcare journalist Anjalee Khemlani will host a virtual roundtable focusing on the treatment of acute agitation linked to neuropsychiatric conditions such as bipolar disorder and schizophrenia. This significant event, sponsored by BioXcel Therapeutics, Inc. (Nasdaq: BTAI), aims to explore emerging self-administered treatments that could revolutionize patient care.
Pre-registration is currently open and can be completed through the following link: Register Here.
The Growing Need for Innovative Treatment Solutions
As millions of patients and caregivers face the challenges of acute agitation episodes—an estimated 57 to 77 million occurrences annually in the U.S.—this roundtable will shed light on how treatment approaches are evolving. Attendees will gain insights into how new innovations can effectively enable care outside emergency rooms, psychiatric facilities, and skilled nursing environments.
Expert Panelists Joining the Discussion
The virtual roundtable will feature esteemed medical professionals, including:
- Leslie Citrome, M.D., M.P.H. - Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College
- Marc A. Milano, M.D., FACEP - Chair, Department of Emergency Medicine at Newark Beth Israel Medical Center and Children’s Hospital of New Jersey
- Leon Ravin, M.D. - Statewide Psychiatric Medical Director for the Division of Public and Behavioral Health, State of Nevada
Participants will have the opportunity to engage in a written Q&A session, allowing for direct interaction with the panelists.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) focuses on using artificial intelligence to develop groundbreaking neuroscience medicines. Its subsidiary, OnkosXcel Therapeutics, aims to innovate therapies in immuno-oncology. The company’s unique drug re-innovation strategy utilizes existing approved drugs alongside advanced data analytics and proprietary machine learning algorithms to discover new therapeutic applications.
For further information about BioXcel Therapeutics, visit bioxceltherapeutics.com.